Summary
12.73 0.07(0.51%)07/01/2024
Novavax, Inc. (NVAX)
Novavax, Inc. (NVAX)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.59 | -9.14 | -30.12 | 173.66 | 153.49 | 72.43 | 124.03 | -84.09 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 12.73 | |
| Open | 12.67 | |
| High | 13.76 | |
| Low | 12.45 | |
| Volume | 7,652,056 | |
| Change | 0.07 | |
| Change % | 0.59 | |
| Avg Volume (20 Days) | 9,111,928 | |
| Volume/Avg Volume (20 Days) Ratio | 0.84 | |
| 52 Week Range | 3.53 - 23.86 | |
| Price vs 52 Week High | -46.67% | |
| Price vs 52 Week Low | 260.48% | |
| Range | 0.43 | |
| Gap Up/Down | -0.40 | |
Fundamentals | ||
| Market Capitalization (Mln) | 1,778 | |
| EBIDTA | -510,985,984 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 15.40 | |
| Book Value | -5.1390 | |
| Earnings Per Share | -5.4100 | |
| EPS Estimate Current Quarter | -1.0600 | |
| EPS Estimate Next Quarter | -0.8500 | |
| EPS Estimate Current Year | -0.7200 | |
| EPS Estimate Next Year | -0.0400 | |
| Diluted EPS (TTM) | -5.4100 | |
| Revenues | ||
| Profit Marging | -0.5541 | |
| Operating Marging (TTM) | -0.6301 | |
| Return on asset (TTM) | -0.1702 | |
| Return on equity (TTM) | -8.9820 | |
| Revenue TTM | 983,705,024 | |
| Revenue per share TTM | 9.7620 | |
| Quarterly Revenue Growth (YOY) | -0.1850 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -156,045,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 1.7816 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 49.5220 | |
| Revenue Enterprise Value | 0.4678 | |
| EBITDA Enterprise Value | -0.5340 | |
| Shares | ||
| Shares Outstanding | 140,403,008 | |
| Shares Float | 123,623,410 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.36 | |
| Insider (%) | 4.99 | |
| Institutions (%) | 59.09 | |
06/29 08:55 EST - fool.com
Where Will Novavax Be in 1 Year?
Novavax recently made a move that improved its financial position and prospects. The biotech has two pivotal clinical trials in the works.
Where Will Novavax Be in 1 Year?
Novavax recently made a move that improved its financial position and prospects. The biotech has two pivotal clinical trials in the works.
06/28 18:52 EST - zacks.com
Novavax (NVAX) Falls More Steeply Than Broader Market: What Investors Need to Know
Novavax (NVAX) reachead $12.66 at the closing of the latest trading day, reflecting a -1.33% change compared to its last close.
Novavax (NVAX) Falls More Steeply Than Broader Market: What Investors Need to Know
Novavax (NVAX) reachead $12.66 at the closing of the latest trading day, reflecting a -1.33% change compared to its last close.
06/28 06:30 EST - investorplace.com
Meme Stock or Vaccine Stock? Novavax's Identity Crisis and Why It Matters for Investors
Does it make sense to invest in COVID-19 vaccine stocks in 2024? It should make sense, at least in theory, since U.S. health regulators effectively gave Novavax (NASDAQ: NVAX ) the green light to target a specific Covid-19 variant.
Meme Stock or Vaccine Stock? Novavax's Identity Crisis and Why It Matters for Investors
Does it make sense to invest in COVID-19 vaccine stocks in 2024? It should make sense, at least in theory, since U.S. health regulators effectively gave Novavax (NASDAQ: NVAX ) the green light to target a specific Covid-19 variant.
06/27 14:21 EST - investorplace.com
You've Been Warned! 3 Biotech Stocks to Buy Now or Regret Forever.
Biotech stocks to buy now reflect a more dynamic shift in investor focus of late.Over the past few years, the biotech space attracted plenty of investor interest, driven by the Covid-19 pandemic. Global vaccine sales for the crippling virus were upwards of $142 billion from 2020 to 2023.
You've Been Warned! 3 Biotech Stocks to Buy Now or Regret Forever.
Biotech stocks to buy now reflect a more dynamic shift in investor focus of late.Over the past few years, the biotech space attracted plenty of investor interest, driven by the Covid-19 pandemic. Global vaccine sales for the crippling virus were upwards of $142 billion from 2020 to 2023.
06/25 12:45 EST - zacks.com
Novavax (NVAX) Seeks Nod for Updated COVID-19 Jab in Europe
Novavax (NVAX) seeks marketing authorization in the European Union for an updated version of its COVID-19 vaccine, which has been formulated to target the JN.1 variant.
Novavax (NVAX) Seeks Nod for Updated COVID-19 Jab in Europe
Novavax (NVAX) seeks marketing authorization in the European Union for an updated version of its COVID-19 vaccine, which has been formulated to target the JN.1 variant.
06/24 10:05 EST - zacks.com
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
06/24 09:18 EST - prnewswire.com
Novavax Submits Application to European Medicines Agency for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine
Novavax's JN.1 COVID-19 vaccine is active against current circulating strains, including KP.2 and KP.3 GAITHERSBURG, Md. , June 24, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it has filed for a type II variation of existing Marketing Authorization with the European Medicines Agency (EMA) for its JN.1 COVID-19 vaccine (NVX-CoV2705) for individuals aged 12 and older.
Novavax Submits Application to European Medicines Agency for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine
Novavax's JN.1 COVID-19 vaccine is active against current circulating strains, including KP.2 and KP.3 GAITHERSBURG, Md. , June 24, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it has filed for a type II variation of existing Marketing Authorization with the European Medicines Agency (EMA) for its JN.1 COVID-19 vaccine (NVX-CoV2705) for individuals aged 12 and older.
06/21 11:24 EST - investors.com
Is Novavax Stock A Buy On Its Covid Vaccine Launch Spree?
Novavax stock jumped this month as the company launched its updated Covid shot abroad. Is NVAX stock a buy or a sell right now?
Is Novavax Stock A Buy On Its Covid Vaccine Launch Spree?
Novavax stock jumped this month as the company launched its updated Covid shot abroad. Is NVAX stock a buy or a sell right now?
06/21 11:24 EST - investors.com
Is Novavax Stock A Sell After New Covid Shot Fails To Bolster Its Outlook?
Novavax stock is on the downswing again after the company cut its outlook for the year. Is NVAX stock a buy or a sell right now?
Is Novavax Stock A Sell After New Covid Shot Fails To Bolster Its Outlook?
Novavax stock is on the downswing again after the company cut its outlook for the year. Is NVAX stock a buy or a sell right now?
06/21 11:24 EST - investors.com
Is Novavax Stock A Buy On A Vaccines Rally Following Bullish Moderna News?
Is Novavax stock a buy after vaccine stocks surged on bullish news from Moderna? Is NVAX stock a buy right now?
Is Novavax Stock A Buy On A Vaccines Rally Following Bullish Moderna News?
Is Novavax stock a buy after vaccine stocks surged on bullish news from Moderna? Is NVAX stock a buy right now?
06/21 11:24 EST - investors.com
Is Novavax Stock A Sell As The Company Braces For A $700 Million Fight?
Novavax stock is under pressure on litigation and competition headwinds. Is NVAX stock a buy or a sell today?
Is Novavax Stock A Sell As The Company Braces For A $700 Million Fight?
Novavax stock is under pressure on litigation and competition headwinds. Is NVAX stock a buy or a sell today?
06/21 11:24 EST - investors.com
Novavax Is No Longer Expected To Become Profitable This Year — Is It A Sell?
Is Novavax stock a sell after its second-quarter disappointment led to a guidance cut? NVAX stock ranks low among biotechs.
Novavax Is No Longer Expected To Become Profitable This Year — Is It A Sell?
Is Novavax stock a sell after its second-quarter disappointment led to a guidance cut? NVAX stock ranks low among biotechs.
06/21 11:24 EST - investors.com
Is Novavax Stock A Buy After Winning A Key Designation From The World Health Organization?
Novavax stock remains under pressure despite winning a key designation for its malaria shot. Is NVAX stock a buy or a sell in January 2024?
Is Novavax Stock A Buy After Winning A Key Designation From The World Health Organization?
Novavax stock remains under pressure despite winning a key designation for its malaria shot. Is NVAX stock a buy or a sell in January 2024?
06/21 11:24 EST - investors.com
Is Novavax A Sell After Its Quarterly Flop Led To A Guidance Cut?
Is Novavax stock a sell after its second-quarter disappointment led to a guidance cut? NVAX stock ranks low among biotechs.
Is Novavax A Sell After Its Quarterly Flop Led To A Guidance Cut?
Is Novavax stock a sell after its second-quarter disappointment led to a guidance cut? NVAX stock ranks low among biotechs.
06/21 11:24 EST - investors.com
The FDA Could, Finally, Approve Novavax's Covid Vaccine — Is Novavax Stock A Buy?
Novavax stock seesawed on June 6 after the FDA assigned an April review date for its Covid vaccine. Is NVAX stock a buy right now?
The FDA Could, Finally, Approve Novavax's Covid Vaccine — Is Novavax Stock A Buy?
Novavax stock seesawed on June 6 after the FDA assigned an April review date for its Covid vaccine. Is NVAX stock a buy right now?
06/21 11:24 EST - investors.com
Is Novavax Stock A Buy As Pressure Mounts For A Covid-19 Vaccine?
Novavax is making a play for a coronavirus vaccine, vs. giants like Pfizer, and other rivals like Moderna.
Is Novavax Stock A Buy As Pressure Mounts For A Covid-19 Vaccine?
Novavax is making a play for a coronavirus vaccine, vs. giants like Pfizer, and other rivals like Moderna.
06/21 11:24 EST - investors.com
Is Novavax Stock A Buy Or A Sell As Shares Stage A Comeback On A Cost-Cutting Plan?
Novavax stock is on the rise after announcing a cost-cutting plan and bullish sales guidance. Is NVAX stock a buy or a sell today?
Is Novavax Stock A Buy Or A Sell As Shares Stage A Comeback On A Cost-Cutting Plan?
Novavax stock is on the rise after announcing a cost-cutting plan and bullish sales guidance. Is NVAX stock a buy or a sell today?
06/20 18:50 EST - zacks.com
Novavax (NVAX) Ascends While Market Falls: Some Facts to Note
In the most recent trading session, Novavax (NVAX) closed at $14.06, indicating a +1.99% shift from the previous trading day.
Novavax (NVAX) Ascends While Market Falls: Some Facts to Note
In the most recent trading session, Novavax (NVAX) closed at $14.06, indicating a +1.99% shift from the previous trading day.
06/18 10:29 EST - investorplace.com
3 Short-Squeeze Stocks Ready to Break the Chains of Bearish Sentiment
It was not long ago that Novavax (NASDAQ: NVAX ) was among the stocks with high short interest. The stock had been trending lower for an extended period.
3 Short-Squeeze Stocks Ready to Break the Chains of Bearish Sentiment
It was not long ago that Novavax (NASDAQ: NVAX ) was among the stocks with high short interest. The stock had been trending lower for an extended period.
06/17 13:05 EST - zacks.com
Novavax (NVAX) Seeks FDA Nod for Updated COVID-19 Vaccine
Novavax (NVAX) seeks FDA???s approval to update its COVID-19 vaccine for the 2024-2025 fall season against current circulating strains, including KP.2 and KP.3.
Novavax (NVAX) Seeks FDA Nod for Updated COVID-19 Vaccine
Novavax (NVAX) seeks FDA???s approval to update its COVID-19 vaccine for the 2024-2025 fall season against current circulating strains, including KP.2 and KP.3.
06/17 09:06 EST - seekingalpha.com
Novavax: Bird Flu And COVID-19 Headlines Trigger Rally
Novavax has seen a surge in stock price due to recent COVID-19 and bird flu vaccine developments, reaching over $27 per share. The company is making headlines with updates on their COVID-19 vaccine, bird flu vaccine, and potential FDA approval, with upcoming catalysts expected. Investors need to consider competition risks, but potential for Novavax to generate revenue and validate their vaccine technology with upcoming clinical trials.
Novavax: Bird Flu And COVID-19 Headlines Trigger Rally
Novavax has seen a surge in stock price due to recent COVID-19 and bird flu vaccine developments, reaching over $27 per share. The company is making headlines with updates on their COVID-19 vaccine, bird flu vaccine, and potential FDA approval, with upcoming catalysts expected. Investors need to consider competition risks, but potential for Novavax to generate revenue and validate their vaccine technology with upcoming clinical trials.
06/14 14:05 EST - prnewswire.com
Novavax Submits Application to U.S. FDA for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine
Novavax's updated JN.1 COVID-19 vaccine is active against current circulating strains, including KP.2 and KP.3 Novavax's JN.1 COVID-19 vaccine would be the only protein-based option available in the U.S. Novavax's filing is aligned with FDA, EMA and WHO global recommendations on vaccine composition Novavax intends to have its vaccine in pre-filled syringes available in the U.S. for immediate release post-authorization and following recommendation by the U.S. CDC GAITHERSBURG, Md. , June 14, 2024 /PRNewswire / -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it has submitted an amendment to its Emergency Use Authorization to the U.S. Food and Drug Administration (FDA) for its updated JN.1 COVID-19 vaccine (NVX-CoV2705) for individuals aged 12 and older.
Novavax Submits Application to U.S. FDA for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine
Novavax's updated JN.1 COVID-19 vaccine is active against current circulating strains, including KP.2 and KP.3 Novavax's JN.1 COVID-19 vaccine would be the only protein-based option available in the U.S. Novavax's filing is aligned with FDA, EMA and WHO global recommendations on vaccine composition Novavax intends to have its vaccine in pre-filled syringes available in the U.S. for immediate release post-authorization and following recommendation by the U.S. CDC GAITHERSBURG, Md. , June 14, 2024 /PRNewswire / -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it has submitted an amendment to its Emergency Use Authorization to the U.S. Food and Drug Administration (FDA) for its updated JN.1 COVID-19 vaccine (NVX-CoV2705) for individuals aged 12 and older.
06/14 04:55 EST - fool.com
Is It Too Late to Buy Novavax Stock?
Novavax's stock is highly volatile due to the company's instability and inconsistent financial results. Sanofi has partnered with the company, and that has sparked a wave of excitement in Novavax's stock.
Is It Too Late to Buy Novavax Stock?
Novavax's stock is highly volatile due to the company's instability and inconsistent financial results. Sanofi has partnered with the company, and that has sparked a wave of excitement in Novavax's stock.
06/13 11:02 EST - investorplace.com
3 Penny Stocks Set to Surge 500% by 2026: June Edition
Penny stocks have the tendency to surprise when it comes to delivering stellar returns at the blink of an eye. A good example is Novavax (NASDAQ: NVAX ) that has delivered 203% returns for year-to-date.
3 Penny Stocks Set to Surge 500% by 2026: June Edition
Penny stocks have the tendency to surprise when it comes to delivering stellar returns at the blink of an eye. A good example is Novavax (NASDAQ: NVAX ) that has delivered 203% returns for year-to-date.
06/13 07:36 EST - marketbeat.com
Top 4 Large-Cap Stocks With Major Short Interest
With the ongoing GameStop saga reigniting interest in meme stocks, investors, or more likely traders and speculators, are once again seeking out stocks with high short interest. As the overall market, the technology sector, and many global-leading household stocks trade near all-time highs, trader's appetite for risk and speculative plays may be increasing.
Top 4 Large-Cap Stocks With Major Short Interest
With the ongoing GameStop saga reigniting interest in meme stocks, investors, or more likely traders and speculators, are once again seeking out stocks with high short interest. As the overall market, the technology sector, and many global-leading household stocks trade near all-time highs, trader's appetite for risk and speculative plays may be increasing.
06/11 06:00 EST - investorplace.com
3 Vaccine Stocks to Buy as the FDA Cracks Down on New Variants
On Friday, the U.S. Federal Drug Administration (FDA) okayed the launch of updated vaccines as part of the 2024-2025 campaign against new Covid strains. Drug manufacturers have been waiting on approval from the agency, whose decision-making was complicated by the fact that the virus keeps mutating.
3 Vaccine Stocks to Buy as the FDA Cracks Down on New Variants
On Friday, the U.S. Federal Drug Administration (FDA) okayed the launch of updated vaccines as part of the 2024-2025 campaign against new Covid strains. Drug manufacturers have been waiting on approval from the agency, whose decision-making was complicated by the fact that the virus keeps mutating.
06/11 05:10 EST - fool.com
Bull Market and Beyond: 3 Stocks Just Waiting to Soar
The S&P 500 has hit more than one record high this year, and technology stocks have led the gains. It's a great idea to get in on stocks that have remained in the doldrums but could have a bright future.
Bull Market and Beyond: 3 Stocks Just Waiting to Soar
The S&P 500 has hit more than one record high this year, and technology stocks have led the gains. It's a great idea to get in on stocks that have remained in the doldrums but could have a bright future.
06/10 15:33 EST - schaeffersresearch.com
3 Biotech Stocks to Monitor Right Now
Last week, we profiled biotech exchange-traded fund (ETF) SPDR S&P Biotech ETF (XBI) amid a historically bullish month.
3 Biotech Stocks to Monitor Right Now
Last week, we profiled biotech exchange-traded fund (ETF) SPDR S&P Biotech ETF (XBI) amid a historically bullish month.
06/10 10:05 EST - zacks.com
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.